Application No.: Not Yet Assigned 2 Docket No.: 05432/100L600-US1

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating The use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABA_B receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and or other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors comprising administering to a person in need thereof a therapeutically effective amount of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABA_B receptor antagonist, inverse agonist or partial agonist.

2. (Canceled)

- 3. (Currently Amended) A method of The use of a GABAB receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor comprising administering a GABA_B receptor antagonist, inverse agonist or partial agonist.
- 4. (Currently Amended) The method use according to any of claims 2-3 claim 3 wherein the serotonin reuptake inhibitor is used for the treatment of depression, anxiety disorders or and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to a SRI serotonin reuptake inhibitor.

Application No.: Not Yet Assigned 3 Docket No.: 05432/100L600-US1

5. (Currently Amended) A method of treating The use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABA_B-receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and or other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors comprising administering to a person in need thereof a therapeutically effective amount of a compound, which is a serotonin reuptake inhibitor, and a compound, which is a GABA_B receptor antagonist, inverse agonist or partial agonist.

- 6. (Currently Amended) The use method according to claim 1 any of claims 1-5 wherein the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor is used.
- 7. (Currently Amended) The use method according to claim 1 any of claims 1-5 wherein a compound, which is the GABA_B receptor antagonist, inverse agonist or partial agonist is selective for the GABA_B receptor, is used.
- 8. (Currently Amended) The use method according to claim 1 any of claims 1-5 or 7 wherein an antagonist or an inverse agonist at the GABA_B receptor is used.
- 9. (Currently Amended) The use method according to claim 8 wherein a GABA_B receptor antagonist is used.
- 10. (Currently Amended) The use method according to claim 1 any of claims 1 6 wherein the SRI serotonin reuptake inhibitor is elected selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramin, femoxetine and clomipramine.

11. (Currently Amended) The use method according to claim 1 claims 1-5 or 7-9 wherein the GABA_B receptor ligand is selected from CGP-71982, CGP-76290, CGP-76291, CGP-35348, CGP-36742, CGP-46381, CGP-52432, CGP-54626, CGP-55845, CGP-62349, SCH 50911, GAS-360, Phaclofen, Saclofen, and 2-hydroxysaclofen.

- 12. (Original) A pharmaceutical composition comprising a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABA_B receptor antagonist, inverse agonist or partial agonist, and optionally pharmaceutically acceptable carriers or diluents.
- 13. (Currently Amended) <u>The A pharmaceutical composition according to claim 12</u> wherein the serotonin reuptake inhibitor used is a selective serotonin reuptake inhibitor.
- 14. (Currently Amended) <u>The A pharmaceutical composition according to claim 12</u> wherein the GABA_B antagonist, inverse agonist of partial agonist is selective for the GABA_B receptor.
- 15. (Currently Amended) <u>The A pharmaceutical composition according to any of claims</u> claim 12 and 14, wherein the GABA_B ligand is a GABA_B receptor antagonist.
- 16. (Currently Amended) <u>The A pharmaceutical composition according to claim any of claims 12 wherein and 13 characterized in that the serotonin uptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramin, femoxetine and clomipramine.</u>
- 17. (Currently Amended) <u>The A pharmaceutical composition according to claim any of</u> 12 and 14-15 characterized in that <u>wherein</u> the GABA_B ligand is selected from CGP-71982, CGP-76290, CGP-76291, CGP-35348, CGP-36742, CGP-46381, CGP-52432, CGP-54626,CGP-55845,CGP-55845, CGP-62349, SCH 50911, GAS-360, Phaclofen, Saclofen of <u>and</u> 2-hydroxysaclofen.

- 18. (Currently Amended) <u>The A pharmaceutical composition according to claim 12 any of claims 12-17</u>, which is adapted for simultaneous administration of the active ingredients.
- 19. (Currently Amended) <u>The A pharmaceutical composition according to claim 18</u> wherein the active ingredients are contained in the same unit dosage form.
- 20. ((Currently Amended) <u>The A pharmaceutical composition according to claim 12 any of claims 12-17</u> which is adapted for sequential administration of the active ingredients.
- 21. (Currently Amended) The pharmaceutical composition according to any of claims claim 18 and 20 wherein the active ingredients are contained in discrete dosage forms.
- 22. (Currently Amended) A method for the identification of compounds useful for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors, comprising, in any order, the steps of (a) and (b):
- (a) measuring the ability of test compounds to inhibit serotonin reuptake and selecting the compounds that have an IC50 value below 20 nM;
- (b) measuring the affinity of test compounds to the GABA_B receptor and selecting the compounds[[,]];

and thereafter

(c) measuring the efficacy of the selected compounds at the GABA_B receptor and selecting the compounds which are antagonists, inverse agonists or partial agonists at the receptor.

Application No.: Not Yet Assigned 6 Docket No.: 05432/100L600-US1

23. (Currently Amended) <u>The</u> A method according to claim 22 wherein the compound has an affinity in step (b) of less than 500 nM.

- 24. (Currently Amended) <u>The A method according to claim any of claims 22 and 23</u>, wherein the compound has an affinity in step (b) of less than 100 nM.
- 25. (Currently Amended) A compound identified according to the method of claim 22 any of the claims 22-24.
- 26. (New) The method according to claim 1, wherein the anxiety disorders and other affective disorders are selected from generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder.
- 27. (New) The method according to claim 1, wherein the eating disorder is selected from bulimia, anorexia, and obesity.
- 28. (New) The method according to claim 3, wherein the anxiety disorders and other affective disorders are selected from generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder.
- 29. (New) The method according to claim 3, wherein the eating disorder is selected from bulimia, anorexia, and obesity.
- 30. (New) The pharmaceutical composition according to claim 20 wherein the active ingredients are contained in discrete dosage forms.